Executive summary
United States Patent 7,803,839 is a high-coverage small-molecule “Markush” compound claim family centered on a 4-(2-fluoro-4-iodoanilide)-substituted, difluoro phenyl core linked to a substituted azetidinyl-3-ol/azetidinone scaffold (Group A variable aryl + Group B variable ring substituents + optional salt/stereochemistry). The independent claim (claim 1) is structurally broad via nested definition of A, X, R1-R7 and heteroatom-bearing substituent classes on multiple positions, while dependent claims progressively pin down: (i) specific halogenation patterns on the difluorophenyl and/or anilide rings, (ii) specific halogen identity at X and R7, (iii) simplified hydrogen-only cases for some positions, and (iv) a very large enumerated “representative” set in claim 23 that effectively anchors the estate to concrete exemplified analogs and stereoisomers. The patent also claims pharmaceutical compositions (claims 24 and 47-68), extending protection to formulations containing the claimed compounds.
Below is a scope-and-claims breakdown of the 7,803,839 estate as written, plus a practical litigation and freedom-to-operate (FTO) view focused on how competitors would design around a Markush-defined azetidinyl scaffold and how an Orange-Book-style product risk would be mapped to specific stereochemistry and substitution patterns.
United States Patent 7,803,839 scope and claim chart: what chemical space is protected?
What is the structural “spine” of claim 1?
Claim 1 is directed to:
- A compound of “formula I” (not reproduced in the text you provided, but the substituent grammar is explicit)
- optionally as a pharmaceutically acceptable salt
- including either:
- a single stereoisomer, or
- a mixture of stereoisomers
The claim then uses a Markush framework where the variable sets are split across:
- A = a substituted phenylene (Group A)
- X = a small carbon linker substituent (Group A: alkyl/halo/haloalkyl/haloalkoxy)
- R1-R7 = substituents on the aromatic and azetidinyl/adjacent positions (Group A plus additional group definitions)
- R8/R8’/R8’’/R9/R10/R12/R14/R16/R25/R25a/R25b/R31-R35 = substituent variables controlling heteroatom identity and substitution patterns
- m = 0, 1, or 2 (used with sulfoxide/sulfone-like options)
Even with the missing “formula I” diagram, your claim language shows a consistent core motif present in claim 23 exemplars: 3-(hydroxymethyl/halogenated phenyl carbamoyl)/azetidinyl-3-ol and related azetidinyl carbonyl forms, with:
- a difluorinated anilide-bearing phenyl (often 3,4-difluoro or closely related difluoro patterns),
- a 2-fluoro-4-iodophenylamino substituent,
- and azetidine substitution at the 3-position (often hydroxyl) and at the azetidine N (varied amide/carbamate/amine) and/or 3-carbon substituent (varied alkyl/alkenyl/heteroaryl substituents).
How broad is the “Markush” coverage?
Broad, because claim 1 includes:
- extensive substitution options on phenylene A (up to four substituents selected from R10/R12/R14/R16)
- multiple substituent classes at R1-R6 and R7
- broad optional substitution “load” on alkyl/alkenyl/heteroaryl fragments (each can carry multiple substituents)
- permissive choices for sulfone/sulfoxide, urea-like carbonyls, amide/carboxamide, and oxime-like “C(═NOH)” forms
This is the highest-value point for enforcement: if a competitor’s final drug candidate lands inside the defined scaffold with the specified halogenation and azetidine substitution options, claim 1 can read broadly without requiring an exact match to the examples.
What patents protect United States Patent 7,803,839 compound families and how many claim tiers exist?
Claim tiers in 7,803,839
Based on your provided claim set, the patent has a layered claim strategy:
- Independent Markush compound claim
- Claim 1: formula I scaffold with fully variable substituent sets.
- Dependent narrowing via Group A constraints
- Claims 2, 11: limit A to halo/H-only substitutions and X to halo, plus restrictions such as R1/R2/R5/R6 = hydrogen.
- Dependent narrowing via specific R3/R4 patterns
- Claims 3-10, 12-16, 19, 20-22: constrain substituents at positions tied to the aromatic/azetidine carbonyl/oxime-like features.
- Dependent narrowing via explicit halogen pattern anchors
- Claims 17-18: specify R7 as iodo/bromo; X as fluoro/chloro; and constrain difluoro positions via R10/R12/R14/R16 hydrogen/fluoro.
- Dependent “exemplified compounds” with enumerated names
- Claim 23: a large list of specific compounds.
- Dependent specific compound + composition claims
- Claims 25-30: stereospecific/identity-specific anchors from the claim 23 list.
- Claims 24, 47-68: pharmaceutical compositions containing a claimed compound.
The “anchor” role of claim 23
Claim 23 enumerates dozens of concrete exemplars and multiple stereoisomer labels. Even though claim 23 is dependent on claim 1, it matters for scope and validity posture because:
- it demonstrates possession of specific members within the broad Markush.
- it provides the best map for what the patent owner expects to be used commercially and what defendants are likely to design around.
- it supports infringement allegations by matching candidate structures to enumerated compound names.
Which specific substituents and stereochemistry choices are explicitly covered?
Halogenation and core substitution anchors
The most repeated anchor in the enumerated list and dependent narrowing claims is a difluoro + 2-fluoro-4-iodo aniline motif:
- Claim 17: “R7 is iodo or bromo; X is fluoro or chloro; R1, R2, R5, and R6 are hydrogen; and R10, R12, R14, and R16 are independently hydrogen or fluoro.”
- Claim 18 further narrows R10/R12/R14/R16 to specific fluoro arrangements (examples given as alternative patterns).
Practical read-across:
- If a competitor keeps the same difluoro phenyl and keeps the anilide bearing 2-fluoro-4-iodophenylamino (or the bromo/iodo “R7” analog with X = fluoro/chloro), they are likely inside claim 1 and claim 17/18 subclasses.
Stereochemistry coverage
Claim 1 explicitly covers:
- a single stereoisomer or a mixture of stereoisomers
- optionally as salts
Claim 23 and claims 25-36 etc. use explicit (R), (S), (±), and cis/trans descriptors for hydroxyl-bearing stereocenters on the azetidine ring system.
Enforcement implication:
- design-around by switching absolute configuration is not a complete shield because claim 1 covers single stereoisomers and mixtures. However, a defendant could still argue non-infringement if their chosen stereochemical member is outside the defined stereochemical variables tied to structure (depending on how “formula I” encodes stereochemistry).
What formulations are protected by 7,803,839? Is it limited to oral dosage forms?
Composition claims
The patent includes:
- Claim 24: a pharmaceutical composition comprising the claimed compound (from claim 1) and a pharmaceutically acceptable carrier/excipient/diluent.
- Claims 47-68: additional composition claims tied to specific enumerated exemplars (claim 23 members), again with pharmaceutically acceptable carriers/excipients/diluents.
Dosage form limitation
None is stated in your provided claim text. The carrier/excipient/diluent formulation language is generic and would capture oral, parenteral, topical, and other standard dosage forms so long as the dosage form contains a covered compound (subject to any claim construction tied to “composition” definition and “pharmaceutically acceptable” context).
How strong is the patent estate for this scaffold: broad claim 1 vs. narrowing dependents
Infringement leverage: broad Markush + enumerated exemplars
From a litigation lens, the strongest enforcement posture comes from:
- claim 1 breadth (covers many substitution classes and multiple positions)
- presence of specific anchored claim 17/18 subclasses (halogen pattern and key position simplifications)
- claim 23 enumerated member list spanning many azetidine-N substituent variations and multiple stereoisomers
That combination reduces the defendant’s ability to argue “we didn’t know which members they owned” or “the patent is too unclear.” It also increases the chance that a real development candidate maps cleanly to one of the enumerated claim 23 members.
Potential weakness: Markush clarity and scope arguments
For defenses, Markush claims can face:
- indefiniteness/enablement challenges (depending on written description support and the breadth of variable substituent permutations)
- non-infringement arguments by targeting substitution patterns outside the defined variable sets
But the claim 23 list suggests possession across numerous substitution patterns, which tends to blunt “no support” arguments in practice.
What generic entry risks exist for drugs containing the azetidinyl difluoro-iodo anilide scaffold?
Key risk factor is whether a generic’s API falls within claim 1
If a generic or follow-on applicant develops a compound member within the formula I Markush, it triggers:
- potential direct infringement (making/selling the API)
- potential indirect infringement (if a drug product includes a covered compound and the marketing triggers infringement)
Orange Book status mapping (method)
This patent is a US utility patent. Your prompt provides no FDA reference product name, NDA/BLA number, or Orange Book listing. Without that linkage, the only defensible way to map generic risk using the patent text is structurally:
- Identify whether the active ingredient (or a prodrug that converts into a covered member) is one of:
- claim 23 enumerated compounds, or
- a different member still within claim 1 variables.
If yes, the generic risk is high because claim 1’s Markush definition is broad and the composition claims extend to the drug product.
How would a competitor design around 7,803,839 at the molecule level?
The claim language suggests several design-out “strike zones,” because infringement requires matching the defined substituent variables.
Likely high-impact design-out levers
- Remove or change the halogen motif tied to the anchor dependent claims
- R7 (iodo/bromo) and X (fluoro/chloro) are explicitly present in claim 17.
- Change substitution identity at R1/R2/R5/R6 if the claim subset requires hydrogen
- Claim 17/2/7 style constraints include hydrogen at R1/R2/R5/R6 in some subclaims.
- Avoid the azetidine substitution classes used in claim 23 members
- Many claim 23 members vary N-substituents (amine, amide, carbamate, oxime, etc.) and C3 substituents (alkyl/alkenyl/aryl).
- A competitor could target a substitution class not captured by the defined R groups in claim 1.
Why design-around is hard
Claim 1’s definitions are extremely permissive:
- multiple heteroatom-bearing substituents allowed at R1-R6 and within R8/R8’/R8’’ and aryl/alkyl optional substitution lists.
That permissiveness narrows the “empty space” where a molecule can land without matching some combination within the Markush.
What patent litigation issues typically matter for this kind of Markush scaffold?
The most litigated claim questions
- Claim construction of variable definitions
- Scope of “optionally substituted” and nested substituent classes
- Whether “independently selected” variables allow any substituent pattern combinations within the same fragment
- Stereochemical infringement
- Whether “single stereoisomer” language in claim 1 requires stereocenter match or whether mixtures broaden the infringement path
- Whether prodrugs or salts satisfy the “optionally as pharmaceutically acceptable salt/solvate” language
- Many competitors use salt forms and polymorphs. This patent includes salt as explicitly optional.
Claim-by-claim scope highlights (high signal only)
Claims 1-6: broad scaffold + core anchoring
- Claim 1: broad Markush compound (formula I) plus salt and stereochemistry.
- Claim 2: A as phenylene with only 1-2 halo/H substituents; X = halo; R1/R2/R5/R6 = H; structured restrictions on R3 and R4.
- Claim 3-6: constrain R3/R4 and/or specific halo at R7 or X.
Claims 7-10: restrict specific groups to hydrogen patterns
- Claim 7: R1, R2, R5, R6 = H.
- Claims 9-10: R3/R4 simplified to small sets (e.g., R3 = hydrogen/halo/hydroxy/amino/alkoxy).
Claims 11-16: narrower A definition and core “hydrogen/hydroxyl/alkyl” substitutions
- Claim 11: A phenylene with 1-2 groups among R10/R12/R14/R16 limited to H/halo.
- Claims 12-16: define R3 and R4 sets (hydrogen, alkyl, heterocycloalkyl; plus hydroxyl at R3 in claim 16).
Claims 17-22: anchor halogen pattern and key substitution simplifications
- Claim 17: “R7 iodo or bromo; X fluoro or chloro; R1/R2/R5/R6 hydrogen; and R10/R12/R14/R16 hydrogen or fluoro.”
- Claim 18: further alternative explicit patterns of fluoro placement.
- Claims 19-22: additional narrowing around R3/R4 and allowed R4 heterocycles/alkyl/aryl.
Claim 23: enumerated exemplars
Claim 23 lists a very large set of specific named compounds, including:
- 3-pyrrolidinyl derivatives
- piperidinyl derivatives
- carbamates/carbamides
- stereoisomer sets (R/S, cis/trans)
- azetidinyl-3-one and oxime variants appear in the earlier part of the list
This is the claim that most directly gives a target for candidate mapping.
Claims 24, 47-68: compositions
Composition claims cover the above compounds with pharmaceutically acceptable carriers/excipients.
Key takeaways
- 7,803,839 is a broad Markush scaffold patent centered on a substituted azetidinyl-3-ol/azetidinyl carbonyl family connected to a difluoro anilide bearing 2-fluoro-4-iodophenylamino (or close bromo/halo analogs), with optional salts and stereochemical coverage.
- Claim 1 is broad enough to capture many substitution patterns; claim 23 provides a strong “anchor” list of specific members across N-substituent classes and stereoisomers.
- The estate also claims pharmaceutical compositions without dosage form limitation, increasing product-level enforcement leverage.
- Competitor design-around will likely focus on breaking the halogen/anchor constraints (R7 and X) and landing substituent identities outside the nested allowed R-group sets.
- Litigation and FTO risk are highest when a development candidate’s API maps to claim 23 members or falls into the claim 1 variable space.
FAQs
-
If a competitor uses the same scaffold but a different salt form, does 7,803,839 still apply?
Yes for pharmaceutically acceptable salts because claim 1 expressly includes optional pharmaceutically acceptable salts.
-
Can a candidate avoid infringement by selling only a single stereoisomer?
Not by stereochemistry alone, because claim 1 covers a single stereoisomer and a mixture.
-
Does 7,803,839 cover drug products or only APIs?
It covers pharmaceutical compositions in claims 24 and 47-68 containing the claimed compounds.
-
What structural element is most likely to control non-infringement for azetidinyl analogs?
The halogen pattern and the allowed substituent classes at the positions tied to R7/X and R1-R6.
-
What evidence inside the patent text most directly supports “representative” coverage?
The large enumerated list in claim 23 of specific exemplified compounds and stereoisomers.
References (APA)
No external sources were provided or cited in the prompt text.
